UNI-BIO GROUP(00690)

0.121+0.0000.00%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Hong Kong Stock Announcement Highlights | Everest MED: Original Product Nefecon® Technology Protected by Valid Chinese Patent ZL200980127272.5
  Stock News · 2025-12-30
  Hong Kong Stock Announcement Highlights | Everest MED: Original Product Nefecon® Technology Protected by Valid Chinese Patent ZL200980127272.5
- BRIEF-Uni-Bio Science Signs Agreement With WMU NERC And Wenzhou Ouhai District Government
  Reuters · 2025-12-30
  BRIEF-Uni-Bio Science Signs Agreement With WMU NERC And Wenzhou Ouhai District Government
- Uni-Bio Science Joins Forces With Wmu Nerc and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strategy Layout
  THOMSON REUTERS · 2025-12-30
  Uni-Bio Science Joins Forces With Wmu Nerc and Ouhai District Government to Build Growth Factor Innovation Ecosystem and Accelerate Regenerative Medicine Strategy Layout
- UNI-BIO GROUP (00690) Enters Strategic Partnership with WMU National Engineering Research Center and Ouhai District Government
  Stock News · 2025-12-30
  UNI-BIO GROUP (00690) Enters Strategic Partnership with WMU National Engineering Research Center and Ouhai District Government
- Uni-Bio Science - Agreement Signed With Wmu Nerc and Wenzhou Ouhai District Government
  THOMSON REUTERS · 2025-12-30
  Uni-Bio Science - Agreement Signed With Wmu Nerc and Wenzhou Ouhai District Government
- Uni-Bio Science - Cooperation to Strengthen R&D in Dermatology, Ophthalmology, Metabolic Diseases, Others
  THOMSON REUTERS · 2025-12-30
  Uni-Bio Science - Cooperation to Strengthen R&D in Dermatology, Ophthalmology, Metabolic Diseases, Others
- Uni-Bio Science Group Partners with WMU NERC and Wenzhou Ouhai Government
  Reuters · 2025-12-30
  Uni-Bio Science Group Partners with WMU NERC and Wenzhou Ouhai Government
- UNI-BIO GROUP (00690): Loan Maturity Date Extended to December 31, 2027
  Stock News · 2025-12-29
  UNI-BIO GROUP (00690): Loan Maturity Date Extended to December 31, 2027
- Uni-Bio Science Extends Secured Loan to PRC Subsidiary
  Reuters · 2025-12-29
  Uni-Bio Science Extends Secured Loan to PRC Subsidiary
- 3 Asian Penny Stocks With Market Caps Up To US$500M
  Simply Wall St. · 2025-12-11
  3 Asian Penny Stocks With Market Caps Up To US$500M
- Uni-Bio Science (00690) Publishes November 2025 Monthly Return
  Bulletin Express · 2025-12-03
  Uni-Bio Science (00690) Publishes November 2025 Monthly Return
- Uni-Bio Science Group Ltd. Announces New Strategic Focus on Regenerative Medicine, Expands Global Collaboration, and Advances Pipeline in Muscular-Skeletal, Skin, Ocular, and ENT Regeneration
  Reuters · 2025-11-24
  Uni-Bio Science Group Ltd. Announces New Strategic Focus on Regenerative Medicine, Expands Global Collaboration, and Advances Pipeline in Muscular-Skeletal, Skin, Ocular, and ENT Regeneration
- Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine
  THOMSON REUTERS · 2025-11-24
  Uni-Bio Science Group Embarks on New Strategy and Launches New Website, Advancing Towards Becoming a Global Leader in Regenerative Medicine
- Uni-Bio Science Group (00690) Publishes Monthly Return for 31 October 2025
  Bulletin Express · 2025-11-03
  Uni-Bio Science Group (00690) Publishes Monthly Return for 31 October 2025
- UNI-BIO GROUP (00690) Shareholders Deposit Shares Worth HK$113 Million into HSBC
  Stock News · 2025-09-24
  UNI-BIO GROUP (00690) Shareholders Deposit Shares Worth HK$113 Million into HSBC
- Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%
  MT Newswires Live · 2025-09-15
  Uni-Bio Science Partners Kexing Biopharm to Commercialize Bogutai in Six Markets; Shares Rise 7%
- BRIEF-Uni-Bio Science's Unit Expands Global Reach Of Bogutai Through Strategic Partnership
  Reuters · 2025-09-12
  BRIEF-Uni-Bio Science's Unit Expands Global Reach Of Bogutai Through Strategic Partnership
- Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®
  Reuters · 2025-09-12
  Uni-Bio Science Group and Kexing Biopharm Form Strategic Alliance to Globalize Osteoporosis Treatment Bogutai®
- Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®
  THOMSON REUTERS · 2025-09-12
  Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®
- UNI-BIO GROUP (00690): Signs Strategic Cooperation Agreement with Kexing Biopharm to Expand Global Market for Bogutai®
  Stock News · 2025-09-12
  UNI-BIO GROUP (00690): Signs Strategic Cooperation Agreement with Kexing Biopharm to Expand Global Market for Bogutai®
Company Profile
Company Name
UNI-BIO GROUP
Market
SEHK
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.uni-bioscience.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Uni-Bio Science Group Limited is a Hong Kong-based investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company operates through four segments. In-house Chemical Pharmaceutical Products segment is engaged in the manufacture and sales of in-house chemical pharmaceutical products. Its chemical pharmaceutical products include Pinapu, among others. In-house Biological Pharmaceutical Products segment is engaged in the manufacture and sales of in-house biological pharmaceutical products. Its biological pharmaceutical products include GeneTime and GeneSoft, among others. In-house Biological Pipeline segment is engaged in the industrialization of in-house biological pipeline. Its biological pipeline products include Uni-E4 and Uni-PTH, among others. Third-party Pharmaceutical Products segment is engaged in the sales of third-party pharmaceutical products.

1D
5D
Day
Week
Month

Loading ...

High

0.121

Open

0.121

Volume%

0.00

Low

0.121

T/O Rate

0.00%

To The Moon

UNI-BIO GROUP(00690)

Company Profile

Most Discussed